neomorph,-inc.

Overview

Neomorph, Inc. is a biotechnology company headquartered in San Diego, California, focusing on discovering and developing innovative medicines by solving critical problems in human health. The company is particularly recognized for its pioneering work in targeted protein degradation, specifically through its proprietary "molecular glue" technology. This approach aims to address 'undruggable' proteins involved in various diseases, thereby offering new therapeutic solutions.

Leadership

• Philip Chamberlain - Co-Founder, President, and CEO. A distinguished leader in biotechnology, he holds a DPhil from the University of Oxford and has been instrumental in strategic partnerships with companies like AbbVie and Biogen, focusing on applying Neomorph's molecular glue technology in oncology and immunology.

• Dr. Klaus Wagner, M.D., Ph.D. - Chief Medical Officer. A seasoned biotech executive and medical oncologist, Dr. Wagner has significant experience in developing oncology therapeutics and aligns Neomorph’s medical strategies with clinical developments.

• Rohan Beckwith, Ph.D. - Vice President of Chemistry. With over 15 years of drug discovery experience, Beckwith advances the corporation's chemistry initiatives, contributing to industry discussions on next-generation degraders and glues.

• Mary Matyskiela, Ph.D. - Vice President of Molecular Sciences. With expertise in the ubiquitin-proteasome field, she is key to expanding Neomorph's druggable genome capabilities and developing molecular glues.

• Ben Wen, Ph.D. - Vice President of Biology. An experienced leader in drug discovery pharmacology with over 15 years of experience, Wen is crucial in advancing Neomorph’s biological research frameworks.

• Ana Grant, Ph.D. - Vice President of Data Sciences. Since April 2023, she has overseen bioinformatics and data workflows to ensure alignment with Neomorph's innovative goals.

• Bell Zhong - Chief Financial Officer. Bringing over 17 years of investment banking and corporate finance expertise from the healthcare and life sciences sectors, Zhong plays a crucial role in financial strategies and operations.

• Samer Chmait - Vice President of Research Operations. Manages all research activities ensuring strategic alignment, leveraging a strong background in scientific operations.

• Megan Gates - Senior Director of Human Resources and Talent Acquisition. Manages HR and recruitment functions, playing a vital role in supporting Neomorph’s growth by building a strong team.

• Marla Bornstein - Vice President of Business Development. With over 20 years of experience, she drives growth strategies and collaborations, including significant partnerships with Novo Nordisk and Biogen.

• Suzana Couto, DVM, PhD, Dipl. ACVP - Senior Vice President of Pathology and Toxicology. Contributes extensive expertise in leading pathology teams to Neomorph's innovative projects.

Strategic Collaborations and Financial Accomplishments

Neomorph has formed several high-profile collaborations to enhance its molecular glue technology. Key partnerships include:

• A collaboration with AbbVie in January 2025 to develop degraders for oncology and immunology.

• A multi-target partnership with Novo Nordisk in February 2024 focusing on treatments for cardiometabolic and rare diseases.

• A partnership with Biogen in October 2024 to target Alzheimer’s disease and rare ailments.

Financially, Neomorph raised $109 million in a Series A financing round in December 2020, directed at advancing its proprietary protein degradation platform and associated programs, underscoring strong investor confidence.

Competitor Profiling

Livzon Pharmaceutical Group

• Established in 1985 and headquartered in Zhuhai, Guangdong, China.

• Focuses on developing Western pharmaceutical preparations, traditional Chinese medicines, and diagnostic reagents.

• Recognized as a National Enterprise Technology Center and involved in SARS-CoV-2 vaccine development.

UCB (Union Chimique Belge)

• Based in Brussels, Belgium, specializing in neurological and autoimmune diseases.

• Global presence with over 9,000 employees focused on delivering value through innovation.

• Acquisitions include Celltech and Schwarz Pharma, reinforcing its biopharma sector standing.

Genentech, Inc.

• A subsidiary of the Roche Group located in South San Francisco, California.

• Specializes in oncology, neuroscience, and ophthalmology.

• Known for developing the first targeted antibody for cancer and groundbreaking scientific contributions.

Cipla Ltd.

• Headquartered in Mumbai, India, with a focus on affordable medications in respiratory and other segments.

• Recognized globally for ensuring access to quality, affordable medicines.

Vividion Therapeutics

• A subsidiary of Bayer AG focusing on small molecule therapeutics.

• Emphasizes undiscovered targets for novel treatments in diseases with high unmet needs.

Competitive Landscape Insights

Neomorph, Inc. operates in a highly competitive biotechnology industry, continually pushing the boundaries of science to develop next-generation therapeutics. Key competitors such as Livzon Pharmaceutical Group, UCB, Genentech, Cipla, and Vividion Therapeutics provide significant insights into potential partnerships, competitive threats, and market opportunities. As Neomorph continues to innovate in protein degradation technology, maintaining focus on evolving market trends and competitor actions will be critical for sustained growth and leadership in the biotechnology sector.